Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2011

Open Access 01-04-2011 | Original Paper

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling

Authors: Chiara Pighi, Ting-Lei Gu, Irene Dalai, Stefano Barbi, Claudia Parolini, Anna Bertolaso, Serena Pedron, Alice Parisi, Jianmin Ren, Daniela Cecconi, Marco Chilosi, Fabio Menestrina, Alberto Zamò

Published in: Cellular Oncology | Issue 2/2011

Login to get access

Abstract

Background

Mantle cell lymphoma (MCL) is currently an incurable entity, and new therapeutic approaches are needed. We have applied a high-throughput phospho-proteomic technique to MCL cell lines to identify activated pathways and we have then validated our data in both cell lines and tumor tissues.

Methods

PhosphoScan analysis was performed on MCL cell lines. Results were validated by flow cytometry and western blotting. Functional validation was performed by blocking the most active pathway in MCL cell lines.

Results

PhosphoScan identified more than 300 tyrosine-phosporylated proteins, among which many protein kinases. The most abundant peptides belonged to proteins connected with B-cell receptor (BCR) signaling. Active BCR signaling was demonstrated by flow cytometry in MCL cells and by western blotting in MCL tumor tissues. Blocking BCR signaling by Syk inhibitor piceatannol induced dose/time-dependent apoptosis in MCL cell lines, as well as several modifications in the phosphorylation status of BCR pathway members and a collapse of cyclin D1 protein levels.

Conclusion

Our data support a pro-survival role of BCR signaling in MCL and suggest that this pathway might be a candidate for therapy. Our findings also suggest that Syk activation patterns might be different in MCL compared to other lymphoma subtypes.
Appendix
Available only for authorised users
Literature
1.
S.H. Swerdlow, E. Campo, M. Seto, H.K. Muller-Hermelink, in Mantle cell lymphoma, in: WHO classification of tumours of haematopoietic and lymphoid tissues, ed. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (IARC Press, Lyon, 2008)
2.
W.K. Hofmann, S. de Vos, K. Tsukasaki, W. Wachsman, G.S. Pinkus, J.W. Said, H.P. Koeffler, Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98, 787–794 (2001)PubMedCrossRef
3.
N. Martinez, F.I. Camacho, P. Algara, A. Rodriguez, A. Dopazo, E. Ruiz-Ballesteros, P. Martin, J.A. Martinez-Climent, J. Garcia-Conde, J. Menarguez, F. Solano, M. Mollejo, M.A. Piris, The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 63, 8226–8232 (2003)PubMed
4.
E. Ortega-Paino, J. Fransson, S. Ek, C.A. Borrebaeck, Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 111, 1617–1624 (2008)PubMedCrossRef
5.
M. Pinyol, S. Bea, L. Pla, V. Ribrag, J. Bosq, A. Rosenwald, E. Campo, P. Jares, Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 109, 5422–5429 (2007)PubMedCrossRef
6.
A. Rinaldi, I. Kwee, M. Taborelli, C. Largo, S. Uccella, V. Martin, G. Poretti, G. Gaidano, G. Calabrese, G. Martinelli, L. Baldini, G. Pruneri, C. Capella, E. Zucca, F.E. Cotter, J.C. Cigudosa, C.V. Catapano, M.G. Tibiletti, F. Bertoni, Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132, 303–316 (2006)PubMedCrossRef
7.
E.G. Rizzatti, R.P. Falcao, R.A. Panepucci, R. Proto-Siqueira, W.T. Anselmo-Lima, O.K. Okamoto, M.A. Zago, Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br. J. Haematol. 130, 516–526 (2005)PubMedCrossRef
8.
A. Rosenwald, G. Wright, A. Wiestner, W.C. Chan, J.M. Connors, E. Campo, R.D. Gascoyne, T.M. Grogan, H.K. Muller-Hermelink, E.B. Smeland, M. Chiorazzi, J.M. Giltnane, E.M. Hurt, H. Zhao, L. Averett, S. Henrickson, L. Yang, J. Powell, W.H. Wilson, E.S. Jaffe, R. Simon, R.D. Klausner, E. Montserrat, F. Bosch, T.C. Greiner, D.D. Weisenburger, W.G. Sanger, B.J. Dave, J.C. Lynch, J. Vose, J.O. Armitage, R.I. Fisher, T.P. Miller, M. LeBlanc, G. Ott, S. Kvaloy, H. Holte, J. Delabie, L.M. Staudt, The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3, 185–197 (2003)PubMedCrossRef
9.
C. Thieblemont, V. Nasser, P. Felman, K. Leroy, S. Gazzo, E. Callet-Bauchu, B. Loriod, S. Granjeaud, P. Gaulard, C. Haioun, A. Traverse-Glehen, L. Baseggio, F. Bertucci, D. Birnbaum, F. Magrangeas, S. Minvielle, H. Avet-Loiseau, G. Salles, B. Coiffier, F. Berger, R. Houlgatte, Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 103, 2727–2737 (2004)PubMedCrossRef
10.
F. Antonucci, M. Chilosi, C. Parolini, M. Hamdan, H. Astner, P.G. Righetti, Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 24, 2376–2385 (2003)PubMedCrossRef
11.
D. Cecconi, A. Zamó, A. Parisi, E. Bianchi, C. Parolini, A.M. Timperio, L. Zolla, M. Chilosi, Induction of apoptosis in Jeko-1 mantle cell lymphoma cell line by resveratrol: a proteomic analysis. J. Proteome Res. 7, 2670–2680 (2008)PubMedCrossRef
12.
I.M. Ghobrial, D.J. McCormick, S.H. Kaufmann, A.A. Leontovich, D.A. Loegering, N.T. Dai, K.L. Krajnik, M.J. Stenson, M.F. Melhem, A.J. Novak, S.M. Ansell, T.E. Witzig, Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood 105, 3722–3730 (2005)PubMedCrossRef
13.
M. Weinkauf, Y. Zimmermann, E. Hartmann, A. Rosenwald, M. Rieken, A. Pastore, G. Hutter, W. Hiddemann, M. Dreyling, 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis 30, 974–986 (2009)PubMedCrossRef
14.
C. Jansen, K.M. Hebeda, M. Linkels, J.M. Grefte, J.M. Raemaekers, J.H. van Krieken, P.J. Groenen, Protein profiling of B-cell lymphomas using tissue biopsies: a potential tool for small samples in pathology. Cell. Oncol. 30, 27–38 (2008)PubMed
15.
C. Jansen, T. Feuth, J.M.M. Raemaekers, J. Rijntjes, J.W. Meijer, P.J. Westenend, J. van Baarlen, J.H.J.M. van Krieken, K.M. Hebeda, P.J.T.A. Groenen, Protein profiling in pathology: analysis and evaluation of 239 frozen tissue biopsies for diagnosis of B-cell lymphomas. Proteomics: Clin. Appl. 4, 519–527 (2010)
16.
H. Stranneheim, L.M. Orre, J. Lehtio, J. Flygare, A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells. Proteome Sci. 7, 43 (2009)PubMedCrossRef
17.
L. Miguet, G. Bechade, L. Fornecker, E. Zink, C. Felden, C. Gervais, R. Herbrecht, A. Van Dorsselaer, L. Mauvieux, S. Sanglier-Cianferani, Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J. Proteome Res. 8, 3346–3354 (2009)PubMedCrossRef
18.
M. Weinkauf, M. Christopeit, W. Hiddemann, M. Dreyling, Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma. Electrophoresis 28, 4416–4426 (2007)PubMedCrossRef
19.
R.S. Boyd, R. Jukes-Jones, R. Walewska, D. Brown, M.J. Dyer, K. Cain, Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol. Cell. Proteomics 8, 1501–1515 (2009)PubMedCrossRef
20.
D. Cecconi, A. Zamo, E. Bianchi, A. Parisi, S. Barbi, A. Milli, S. Rinalducci, A. Rosenwald, E. Hartmann, L. Zolla, M. Chilosi, Signal transduction pathways of mantle cell lymphoma: a phosphoproteome-based study. Proteomics 8, 4495–4506 (2008)PubMedCrossRef
21.
M. Weinkauf, W. Hiddemann, M. Dreyling, Sample pooling in 2-D gel electrophoresis: a new approach to reduce nonspecific expression background. Electrophoresis 27, 4555–4558 (2006)PubMedCrossRef
22.
J. Rush, A. Moritz, K.A. Lee, A. Guo, V.L. Goss, E.J. Spek, H. Zhang, X.M. Zha, R.D. Polakiewicz, M.J. Comb, Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94–101 (2005)PubMedCrossRef
23.
K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J.M. Ren, J. Yuan, C.E. Bakalarski, J. Villen, J.M. Kornhauser, B. Smith, D. Li, X. Zhou, S.P. Gygi, T.L. Gu, R.D. Polakiewicz, J. Rush, M.J. Comb, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007)PubMedCrossRef
24.
J. Carretero, T. Shimamura, K. Rikova, A.L. Jackson, M.D. Wilkerson, C.L. Borgman, M.S. Buttarazzi, B.A. Sanofsky, K.L. McNamara, K.A. Brandstetter, Z.E. Walton, T.L. Gu, J.C. Silva, K. Crosby, G.I. Shapiro, S.M. Maira, H. Ji, D.H. Castrillon, C.F. Kim, C. Garcia-Echeverria, N. Bardeesy, N.E. Sharpless, N.D. Hayes, W.Y. Kim, J.A. Engelman, K.K. Wong, Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17 547–559
25.
D.K. Walters, V.L. Goss, E.P. Stoffregen, T.L. Gu, K. Lee, J. Nardone, L. McGreevey, M.C. Heinrich, M.W. Deininger, R. Polakiewicz, B.J. Druker, Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk. Res. 30, 1097–1104 (2006)PubMedCrossRef
26.
V.L. Goss, K.A. Lee, A. Moritz, J. Nardone, E.J. Spek, J. MacNeill, J. Rush, M.J. Comb, R.D. Polakiewicz, A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 107, 4888–4897 (2006)PubMedCrossRef
27.
T.L. Gu, V.L. Goss, C. Reeves, L. Popova, J. Nardone, J. Macneill, D.K. Walters, Y. Wang, J. Rush, M.J. Comb, B.J. Druker, R.D. Polakiewicz, Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108, 4202–4204 (2006)PubMedCrossRef
28.
T.L. Gu, J. Cherry, M. Tucker, J. Wu, C. Reeves, R.D. Polakiewicz, Identification of activated Tnk1 kinase in Hodgkin’s lymphoma. Leukemia 24 861–865.
29.
S. Bea, I. Salaverria, L. Armengol, M. Pinyol, V. Fernandez, E.M. Hartmann, P. Jares, V. Amador, L. Hernandez, A. Navarro, G. Ott, A. Rosenwald, X. Estivill, E. Campo, Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 113, 3059–3069 (2009)PubMedCrossRef
30.
F. Rubio-Moscardo, J. Climent, R. Siebert, M.A. Piris, J.I. Martin-Subero, I. Nielander, J. Garcia-Conde, M.J. Dyer, M.J. Terol, D. Pinkel, J.A. Martinez-Climent, Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105, 4445–4454 (2005)PubMedCrossRef
31.
I. Vater, F. Wagner, M. Kreuz, H. Berger, J.I. Martin-Subero, C. Pott, J.A. Martinez-Climent, W. Klapper, K. Krause, M.J. Dyer, S. Gesk, L. Harder, A. Zamo, M. Dreyling, D. Hasenclever, N. Arnold, R. Siebert, GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br. J. Haematol. 144, 317–331 (2009)PubMedCrossRef
32.
D. Hui, T. Reiman, J. Hanson, R. Linford, W. Wong, A. Belch, R. Lai, Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod. Pathol. 18, 1223–1231 (2005)PubMedCrossRef
33.
F. Jardin, J.M. Picquenot, F. Parmentier, P. Ruminy, M. Cornic, D. Penther, P. Bertrand, H. Lanic, O. Cassuto, C. Humbrecht, E. Lemasle, A. Wautier, C. Bastard, H. Tilly, Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value. Br. J. Haematol. (2009)
34.
H. Tagawa, S. Karnan, R. Suzuki, K. Matsuo, X. Zhang, A. Ota, Y. Morishima, S. Nakamura, M. Seto, Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene. BIM Oncogene 24, 1348–1358 (2005)CrossRef
35.
Y.Y. Cho, F. Tang, K. Yao, C. Lu, F. Zhu, D. Zheng, A. Pugliese, A.M. Bode, Z. Dong, Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res. 69, 272–281 (2009)PubMedCrossRef
36.
D. Zheng, Y.Y. Cho, A.T. Lau, J. Zhang, W.Y. Ma, A.M. Bode, Z. Dong, Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res. 68, 7650–7660 (2008)PubMedCrossRef
37.
H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono, M. Kanehisa, KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 27, 29–34 (1999)PubMedCrossRef
38.
L. Chen, S. Monti, P. Juszczynski, J. Daley, W. Chen, T.E. Witzig, T.M. Habermann, J.L. Kutok, M.A. Shipp, SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111, 2230–2237 (2008)PubMedCrossRef
39.
R.E. Davis, V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, P.B. Romesser, H. Kohlhammer, L. Lamy, H. Zhao, Y. Yang, W. Xu, A.L. Shaffer, G. Wright, W. Xiao, J. Powell, J.K. Jiang, C.J. Thomas, A. Rosenwald, G. Ott, H.K. Muller-Hermelink, R.D. Gascoyne, J.M. Connors, N.A. Johnson, L.M. Rimsza, E. Campo, E.S. Jaffe, W.H. Wilson, J. Delabie, E.B. Smeland, R.I. Fisher, R.M. Braziel, R.R. Tubbs, J.R. Cook, D.D. Weisenburger, W.C. Chan, S.K. Pierce, L.M. Staudt, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463 88–92
40.
S. Gobessi, L. Laurenti, P.G. Longo, L. Carsetti, V. Berno, S. Sica, G. Leone, D.G. Efremov, Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23, 686–697 (2009)PubMedCrossRef
41.
J.W. Friedberg, J. Sharman, J. Sweetenham, P.B. Johnston, J.M. Vose, A. Lacasce, J. Schaefer-Cutillo, S. De Vos, R. Sinha, J.P. Leonard, L.D. Cripe, S.A. Gregory, M.P. Sterba, A.M. Lowe, R. Levy, M.A. Shipp, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115 2578–2585
42.
J.M. Oliver, D.L. Burg, B.S. Wilson, J.L. McLaughlin, R.L. Geahlen, Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J. Biol. Chem. 269, 29697–29703 (1994)PubMed
43.
L. Leseux, S.M. Hamdi, T. Al Saati, F. Capilla, C. Recher, G. Laurent, C. Bezombes, Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108, 4156–4162 (2006)PubMedCrossRef
44.
A. Rinaldi, I. Kwee, M. Taborelli, C. Largo, S. Uccella, V. Martin, G. Poretti, G. Gaidano, G. Calabrese, G. Martinelli, L. Baldini, G. Pruneri, C. Capella, E. Zucca, F.E. Cotter, J.C. Cigudosa, C.V. Catapano, M.G. Tibiletti, F. Bertoni, Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132, 303–316 (2006)PubMedCrossRef
45.
J. Ennaciri, D. Girard, IL-4R(alpha), a new member that associates with Syk kinase: implication in IL-4-induced human neutrophil functions. J. Immunol. 183, 5261–5269 (2009)PubMedCrossRef
46.
L. Wang, E. Devarajan, J. He, S.P. Reddy, J.L. Dai, Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression. Cancer Res. 65, 10289–10297 (2005)PubMedCrossRef
47.
F.M. Uckun, S. Qazi, H. Ma, L. Tuel-Ahlgren, Z. Ozer, STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc. Natl. Acad. Sci. U S A 107 2902–2907.
48.
F. Baran-Marszak, M. Boukhiar, S. Harel, C. Laguillier, C. Roger, R. Gressin, A. Martin, R. Fagard, N. Varin-Blank, F. Ajchenbaum-Cymbalista, D. Ledoux, Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica 95, 1865–1872 (2010)PubMedCrossRef
49.
L.V. Pham, A.T. Tamayo, C. Li, W. Bornmann, W. Priebe, R.J. Ford, Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol. Cancer Ther. 9, 2026–2036 (2010)PubMedCrossRef
50.
S. Tauzin, H. Ding, K. Khatib, I. Ahmad, D. Burdevet, G. van Echten-Deckert, J.A. Lindquist, B. Schraven, N.U. Din, B. Borisch, D.C. Hoessli, Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood 111, 2310–2320 (2008)PubMedCrossRef
51.
M.A. Yared, J.D. Khoury, L.J. Medeiros, G.Z. Rassidakis, R. Lai, Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch. Pathol. Lab. Med. 129, 990–996 (2005)PubMed
52.
R. Lai, G.Z. Rassidakis, L.J. Medeiros, V. Leventaki, M. Keating, T.J. McDonnell, Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J. Pathol. 199, 84–89 (2003)PubMedCrossRef
53.
J.A. Diehl, M. Cheng, M.F. Roussel, C.J. Sherr, Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499–3511 (1998)PubMedCrossRef
54.
J. Camps, I. Salaverria, M.J. Garcia, E. Prat, S. Bea, J.C. Pole, L. Hernandez, J. Del Rey, J.C. Cigudosa, M. Bernues, C. Caldas, D. Colomer, R. Miro, E. Campo, Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk. Res. 30, 923–934 (2006)PubMedCrossRef
55.
S.W. Tait, D.R. Green, Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11, 621–632 (2010)PubMedCrossRef
56.
T. Miyashita, J.C. Reed, Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293–299 (1995)PubMedCrossRef
57.
F. Zhou, J. Hu, H. Ma, M.L. Harrison, R.L. Geahlen, Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase. Mol. Cell. Biol. 26, 3478–3491 (2006)PubMedCrossRef
58.
L. Wang, L. Duke, P.S. Zhang, R.B. Arlinghaus, W.F. Symmans, A. Sahin, R. Mendez, J.L. Dai, Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 63, 4724–4730 (2003)PubMed
59.
L. Bordin, C. Fiore, M. Bragadin, A.M. Brunati, G. Clari, Regulation of membrane band 3 Tyr-phosphorylation by proteolysis of p72(Syk) and possible involvement in senescence process. Acta. Biochim. Biophys. Sin. (Shanghai) 41, 846–851 (2009)CrossRef
60.
A. Zamo, G. Ott, T. Katzenberger, P. Adam, C. Parolini, A. Scarpa, M. Lestani, F. Menestrina, M. Chilosi, Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica 91, 40–47 (2006)PubMed
61.
G. Dennis Jr., B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, H.C. Lane, R.A. Lempicki, DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, P3 (2003)PubMedCrossRef
Metadata
Title
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
Authors
Chiara Pighi
Ting-Lei Gu
Irene Dalai
Stefano Barbi
Claudia Parolini
Anna Bertolaso
Serena Pedron
Alice Parisi
Jianmin Ren
Daniela Cecconi
Marco Chilosi
Fabio Menestrina
Alberto Zamò
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2011
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-011-0019-7

Other articles of this Issue 2/2011

Cellular Oncology 2/2011 Go to the issue

Original Paper

In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription

Original Paper

Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells

Original Paper

Pathology of hereditary breast cancer

Original Paper

Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case–control study

Original Paper

Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers

Original Paper

Low frequency of HER2 amplification and overexpression in early onset gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits